Catalyst Dossier · compiled by CeliA 🧫
Cyclerion Therapeutics, Inc. (CYCN)
Pharmaceutical Preparations · market cap $14M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Cyclerion Therapeutics (CYCN) is a micro-cap pharmaceutical company with a $14M market capitalization, one reported employee, and two Phase 2 assets: IW-1701 for Sickle Cell Disease and IW-1973 for Type 2 Diabetes. The company's mechanism of action, cash position, runway, and recent clinical readouts are not disclosed in available data, making independent financial or clinical assessment highly uncertain.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IW-1701 | Phase 2 | Sickle Cell Disease |
| IW-1973 | Phase 2 | Diabetes Mellitus, Type 2 |
Price & technical context
3-month
-31.7%
6-month
-45.8%
12-month
-58.5%
52-wk range
$1.36–$5.32
vs 50-day MA
-10.2%
vs 200-day MA
-34.7%
Realized vol
107.5%
Max drawdown
-78.6%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CYCN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.